ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 128 full-time employees. The company went IPO on 2004-03-17. The Company’s principal activity includes development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy - non- invasive cancer diagnostics and HyCEAD multiplex analysis system. The Parsortix system captures circulating tumor cells (CTCs) which cause cancer metastasis and harvests them for analysis. The Parsortix PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA (dipotassium ethylenediaminetetraacetic acid) tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood.

AGL.L Profile, Market Tickers and Other

AGL.L profile

AGL.L market tickers